Mechanism of Tumor-Platelet Communications in Cancer.

Autor:	Dudiki T; Departments of Neurosciences, Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, OH (T.D., M.V., I.Z., S.B., P.F., E.A.P., T.V.B.)., Veleeparambil M; Departments of Neurosciences, Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, OH (T.D., M.V., I.Z., S.B., P.F., E.A.P., T.V.B.)., Zhevlakova I; Departments of Neurosciences, Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, OH (T.D., M.V., I.Z., S.B., P.F., E.A.P., T.V.B.)., Biswas S; Departments of Neurosciences, Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, OH (T.D., M.V., I.Z., S.B., P.F., E.A.P., T.V.B.)., Klein EA; Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Education Institute, Cleveland Clinic, OH (E.A.K.)., Ford P; Departments of Neurosciences, Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, OH (T.D., M.V., I.Z., S.B., P.F., E.A.P., T.V.B.)., Podrez EA; Departments of Neurosciences, Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, OH (T.D., M.V., I.Z., S.B., P.F., E.A.P., T.V.B.)., Byzova TV; Departments of Neurosciences, Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, OH (T.D., M.V., I.Z., S.B., P.F., E.A.P., T.V.B.).
Jazyk:	angličtina
Zdroj:	Circulation research [Circ Res] 2023 May 26; Vol. 132 (11), pp. 1447-1461. Date of Electronic Publication: 2023 May 05.
DOI:	10.1161/CIRCRESAHA.122.321861
Abstrakt:	Background: Thrombosis is one of the main complications in cancer patients often leading to mortality. However, the mechanisms underlying platelet hyperactivation are poorly understood. Methods: Murine and human platelets were isolated and treated with small extracellular vesicles (sEVs) from various cancer cell lines. The effects of these cancer-sEVs on platelets were evaluated both in vitro and in vivo using various approaches, including the detection of cancer-sEV-specific markers in murine platelets and patient samples, measurement of platelet activation and thrombosis assays. Signaling events induced by cancer-sEVs and leading to platelet activation were identified, and the use of blocking antibodies to prevent thrombosis was demonstrated. Results: We demonstrate that platelets very effectively take up sEVs from aggressive cancer cells. The process of uptake is fast, proceeds effectively in circulation in mice, and is mediated by the abundant sEV membrane protein-CD63. The uptake of cancer-sEVs leads to the accumulation of cancer cell-specific RNA in platelets in vitro and in vivo. The human prostate cancer-sEV-specific RNA marker PCA3 is detected in platelets of ~70% of prostate cancer patients. This was markedly reduced after prostatectomy. In vitro studies showed that platelet uptake of cancer-sEVs induces strong platelet activation in a CD63-RPTPα (receptor-like protein tyrosine phosphatase alpha)-dependent manner. In contrast to physiological agonists ADP and thrombin, cancer-sEVs activate platelets via a noncanonical mechanism. Intravital studies demonstrated accelerated thrombosis both in murine tumor models and in mice that received intravenous injections of cancer-sEVs. The prothrombotic effects of cancer-sEVs were rescued by blocking CD63. Conclusions: Tumors communicate with platelets by means of sEVs, which deliver cancer markers and activate platelets in a CD63-dependent manner leading to thrombosis. This emphasizes the diagnostic and prognostic value of platelet-associated cancer markers and identifies new pathways for intervention. Competing Interests: Disclosures None.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu